Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Watson, Venita Gresham ^a   Motsinger Reif, Alison ^b   Hardison, Nicholas E ^b   Peters, Eric J ^a   Havener, Tammy M ^a   Everitt, Lorraine ^a   Auman, James Todd ^a   Comins, Daniel L ^b   McLeod, Howard L ^a  

^a University of North Carolina   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 10 METHOXYCAMPTOTHECIN; 7 CHLOROCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; IRINOTECAN; RUBITECAN; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CEPH CELL LINE; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME 3; CHROMOSOME 4; CHROMOSOME 5; CHROMOSOME 6; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; GENETIC MARKER; HERITABILITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIMIT OF DETECTION; LINKAGE ANALYSIS; QUANTITATIVE TRAIT LOCUS; CELL SURVIVAL; CHROMOSOME MAP; DRUG EFFECT; GENETIC LINKAGE; GENETICS; PEDIGREE;

CAMPTOTHECIN; CELL LINE; CELL SURVIVAL; CHROMOSOME MAPPING; GENETIC LINKAGE; HUMANS; INHIBITORY CONCENTRATION 50; PEDIGREE; QUANTITATIVE TRAIT LOCI; TOPOISOMERASE I INHIBITORS;

EID: 79955832037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017561     Document Type: Article

References (41)

1. Gresham V, McLeod HL, (2009) Genomics: Applications in mechanism elucidation. Advanced Drug Delivery Reviews 61: 369-374.
2. Baetz K, McHardy L, Gable K, Tarling T, Rebérioux D, et al. (2004) Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci U S A 101: 4525-4530.
3. Parsons A, Lopez A, Givoni IE, Williams DE, Gray CA, et al. (2006) Exploring the mode-of-action of bioactive drugs by chemical-genetic profiling in yeast. Cell 126: 611-625.
4. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
5. Blower PE, Yang C, Fligner MA, Verducci MS, Yu L, et al. (2002) Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2: 259-271.
6. Watters JW, Kraja A, Meucci M, Province MA, McLeod HL, (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 101: 11809-11814.
7. Peters EJ, Kraja A, Lin SJ, Yen-Revellow JL, Marsh S, et al. (2009) Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics 19: 399-401.
8. Beretta GL, Perego P, Zunino F, (2006) Mechanisms of Cellular Resistance to Camptothecins. Curr Med Chem Anticancer Agents Bentham Science Publishers Ltd pp. 3291-3305.
9. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
10. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y, (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842.
11. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, et al. (2009) Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61: 413-429.
12. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, et al. (2008) Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 4: e1000287.
13. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A, (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111: 2785-2789.
14. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, et al. (2007) Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 67: 5425-5433.
15. Ulukan H, Swaan PW, (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62: 2039-2057.
16. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, et al. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527.
17. Guo Y, Weller P, Farrell E, Cheung P, Fitch B, et al. (2006) In silico pharmacogenetics of warfarin metabolism. Nat Biotechnol 24: 531-536.
18. Hill R, (2000) NK1 (substance P) receptor antagonists- why are they not analgesic in humans? Trends Pharmacol Sci 21: 244-246.
19. Borrell B, (2010) How accurate are cancer cell lines? Nature 463: 858.
20. Nakatsu N, Yoshida Y, Yamazaki, Nakamura T, Dan S, et al. (2005) Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Molecular Cancer Therapeutics 4: 399-412.
21. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
22. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
23. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG, (2009) Genetic analysis of radiation-induced changes in human gene expression. Nature 459: 587-591.
24. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
25. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, et al. (2003) Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity. Clinical Cancer Res 9: 2856-2865.
26. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, et al. (2007) Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 104: 232-242.
27. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, et al. (2003) Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 63: 2782-2793.
28. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, et al. (2002) Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 62: 1688-1695.
29. Beretta GL, Perego P, Zunino F, (2008) Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets 12: 1243-1256.
30. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, et al. (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26: 9377-9386.
31. Huang RY, Eddy M, Vujcic M, Kowalski D, (2005) Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 65: 5890-5897.
32. MacKeigan JP, Murphy LO, Blenis J, (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7: 591-600.
33. Silva JM, Marran K, Parker JS, Silva J, Golding M, et al. (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617-620.
34. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, et al. (2008) Cancer proliferation gene discovery through functional genomics. Science 319: 620-624.
35. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, et al. (1990) Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6: 575-577.
36. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, et al. (2004) Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64: 4353-4356.
37. RDC Team (2005) R: A language and environment for statistical computing Vienna, Austria R Foundation for Statistical Computing Available: http://www.R-project.org.
38. Abecasis GR, Cherny SS, Cookson WO, Cardon LR, (2002) Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30: 97-101.
39. Cohen D, Chumakov I, Weissenbach J, (1993) A first-generation physical map of the human genome. Nature 366: 698-701.
40. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL, (1998) Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet 63: 861-869.
41. Lander E, Kruglyak L, (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11: 241-247.